Scott Beau, MD
Clinical Cardiac Electrophysiology · Little Rock, ARNPI 1861485302
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,919 of the $6,319 with a category attached, or 77.8%. 21 manufacturers reported payments, led by Abbott at 59.6% of the total. Reporting peaked in 2019 at $3,183 and has fallen 81.3% since, to $596 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in AR, where the typical reported total is $22,678.
Across 98 payments — averaging $64.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$626
- Atricure, Inc.$553
- Avinger Inc.$271
- Medtronic$253
- Philips North America LLC$193
- plus $659 from 15 others
Across 37 payments — averaging $2339.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$67K
- Elutia, Inc.$20K
What the payments were for
- Consulting fees$1,40022%
- Food & beverage$4,91978%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 51 | $3,765 |
| Boston Scientific | 8 | $626 |
| Atricure, Inc. | 5 | $553 |
| Avinger Inc. | 3 | $271 |
| Medtronic(2 entities) | 3 | $253 |
| Philips North America LLC | 2 | $193 |
| Abiomed | 1 | $151 |
| Penumbra, Inc. | 1 | $66 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $59 |
| Novartis | 3 | $59 |
| Elutia, Inc. | 3 | $51 |
| Biotronik Inc. | 2 | $49 |
| Johnson & Johnson | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Novo Nordisk | 2 | $37 |
| Inari Medical, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Cardiva Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assurity Pacemaker$1,400
- AVEIR$600
- EPI-SENSE GUIDED COAGULATION SYS$278
- PANTHERIS$234
- Micra$169
- CardioMEMS HF System$152
- Impella$151
- Quadra Assura CRT Defibrillator$150
- EMBLEM$139
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS$138
- QUADRA ASSURA$126
- RESONATE$121
- MitraClip$111
- MAESTRO 4000$108
- GlideLight$102
- GENERAL - STRUCTURAL HEART$101
How this compares
$6,319 in reported general payments places this provider in the 10th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
See all clinical cardiac electrophysiology providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,441 | $1,191,766 |
| XareltoRivaroxaban | 445 | $408,770 |
| EntrestoSacubitril/Valsartan | 376 | $321,826 |
| MultaqDronedarone Hcl | 237 | $237,955 |
| Dofetilide | 201 | $38,311 |
| FarxigaDapagliflozin Propanediol | 14 | $12,052 |
| Mexiletine Hcl | 153 | $11,873 |
| JardianceEmpagliflozin | 17 | $11,179 |
| Metoprolol Succinate | 662 | $9,315 |
| Potassium Chloride | 307 | $6,220 |
| VascepaIcosapent Ethyl | 14 | $5,422 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $5,090 |
| Flecainide Acetate | 126 | $4,909 |
| Losartan Potassium | 488 | $4,107 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $3,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $42 | $408,770445 claims |
| NovartisEntresto | $59 | $321,826376 claims |
| Sanofi-aventis U.S. LLCMultaq | $20 | $237,955237 claims |
| AstraZenecaFarxiga | $16 | $12,05214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
Other clinical cardiac electrophysiology in Little Rock
- Monica LoLittle Rock$190K
- Sudarone ThihalolipavanLittle Rock$77K
- Prabhat HebbarLittle Rock$75K
- Gerald GreerLittle Rock$41K
- Risheek KaulLittle Rock$38K
- Michael LoguidiceLittle Rock$29K
- Breck SandvallLittle Rock$23K
- Brian NorrisLittle Rock$18K
- Thomas WallaceLittle Rock$14K
- Subodh DevabhaktuniLittle Rock$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.